Mylan Inc (MYL)

MYL (NASDAQ:Drugs)
$49.46
pos +0.69
+1.41%
Today's Range: 48.63 - 50.12 | MYL Avg Daily Volume: 4,910,000
Last Update: 10/17/14 - 4:00 PM EDT
Volume: 4,412,364
YTD Performance: 13.96%
Open: $49.95
Previous Close: $48.77
52 Week Range: $36.97 - $57.52
Oustanding Shares: 374,047,341
Market Cap: 18,242,288,821
6-Month Chart
TheStreet Ratings Grade for MYL
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 10 11
Moderate Buy 0 0 0 0
Hold 2 2 2 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.36 1.36 1.33 1.17
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 33.18
Price Earnings Comparisons:
MYL Sector Avg. S&P 500
33.18 33.30 26.85
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-3.83% 24.55% 185.24%
GROWTH 12 Mo 3 Yr CAGR
Revenue 1.70 0.27 0.08
Net Income -2.60 0.81 0.22
EPS 3.70 1.36 0.33
Earnings for MYL:
EBITDA 1.64B
Revenue 6.91B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $1.14 $0.98 $3.49 $4.02
Number of Analysts 3 6 3 8
High Estimate $1.15 $1.02 $3.52 $4.21
Low Estimate $1.12 $0.94 $3.45 $3.69
Prior Year $0.82 $0.78 $2.89 $3.49
Growth Rate (Year over Year) 38.62% 26.07% 20.65% 15.22%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bullishMylan estimates, target boosted at BMO

Oct 6, 2014 | 8:10 AM EDT

Shares of MYL now seen reaching $42, according to BMO Capital. Estimates also upped, given the company's new guidance. Underperform rating. 

By

Robert Moreno

 | Sep 29, 2014 | 2:40 PM EDT

Four stocks that have been trading in triangle or wedge patterns.

By

Doug Kass

 | Sep 23, 2014 | 8:04 AM EDT
Where it began.

updateMYL Investor Mtg.

Sep 18, 2014 | 7:01 AM EDT

MYL - Mylan Inc Investor Day - NY

By

James "Rev Shark" DePorre

 | Jul 16, 2014 | 4:20 PM EDT

And a paucity of perky charts.

By

Doug Kass

 | Jul 14, 2014 | 8:06 AM EDT
Where it began.
By

Jim Cramer

 | Jul 7, 2014 | 11:18 AM EDT

A wave of M&A in the health sector makes sense.

By

Sham Gad

 | May 15, 2014 | 1:30 PM EDT

I will explore Gannett because I love firms with many owned assets.

bullishMylan upgraded at Citi

Apr 7, 2014 | 7:57 AM EDT

MYL was upgraded to Buy, Citigroup said. $61 price target. Meda purchase appears to make strategic and financial sense. 

bearishMylan estimates, target cut at Leerink

Apr 4, 2014 | 8:10 AM EDT

Shares of MYL now seen reaching $58, according to Leerink Swann. Estimates also reduced, given prescription trends and new product delays. Outperform rating. 

IBM Corporation (IBM) dominating earnings chatter after disappointing badly with results a...
Collins:  
IBM
For all those thinking this was a low risk due to solid finances type of longer term play,...
There sure are a lot of folks calling a market bottom. I don't play that game but even if ...
In preparation for the open of Monday's regular session auction, traders should note that ...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.